This project seeks to use linked administrative data to examine the patterns of use of prescribed opioids, quantify the risks of adverse outcomes, and examine the population-level impact of changes to regulation and subsidy of opioids.
Retaining patients in buprenorphine treatment is essential in maximising treatment outcomes and minimising mortality risk. Delivery of treatment via novel depot buprenorphine products has the potential to enhance patient adherence and retention in treatment.
This project will used linked administrative data to understand risk for mortality and other adverse outcomes during and after opioid agonist treatment (OAT). It will use standard biostatistical approaches and sophisticated machine learning techniques.
This is a PhD project of Vivienne Moxham-Hall (supervised by Professor Alison Ritter and Dr Caitlin Hughes) investigating the utility of indexes as a measure of drug policy.
This is the PhD project of Ms Shann Hulme.
National and international evidence indicates that the non-medical use of pharmaceutical drugs is increasing, along with the associated health, social and economic harms.
Tapentadol is a centrally acting opioid analgesic with dual mechanisms of action, specifically µ-opioid receptor agonist and noradrenaline reuptake inhibition. This dual action is thought to result in a lower dose required to produce a given level of analgesia.
This project aims to embed screening for key pain-related outcomes and emerging problems with pharmaceutical opioids into community pharmacy practice.
We have developed a multidisciplinary global consortium of researchers who can provide independent high-quality evidence regarding the scale of illicit drug use, harms, access to services at country, regional and global levels, and build capacity for better data in these areas.
Over the past few years, there has been a significant increase in the number of seizures and unintentional overdose fatalities related to illicit synthetic opioids in multiple states across the U.S.